Celecoxib decreases liver cancer cells proliferation and metastasis by addressing PNO1 and reduces AKT/c-Met-induced hepatocarcinogenesis by inhibiting COX-2/Akt/FASN pathway [249, 251, 252]. The gene discussed is AKT1; the disease is liver cancer.